Transfer Pricing Tool
for Healthcare

Transfer pricing for Healthcare: OECD methodology

Healthcare and pharmaceutical transfer pricing is among the most complex and highest-value areas of international tax planning. The pharmaceutical industry is built on intellectual property — patents, regulatory approvals, clinical trial data, manufacturing know-how, and brand names — and the allocation of returns from these intangibles between group entities is the central transfer pricing issue. Under the OECD's DEMPE framework (Development, Enhancement, Maintenance, Protection, Exploitation), the entity that performs and controls these functions and bears the associated risks is entitled to the residual profit from the intangible, regardless of legal ownership.

For contract research organisations (CROs) and routine laboratory services within a healthcare group, Cost Plus or TNMM are the standard methods. A CRO that performs clinical trials under the direction of the IP-owning principal, using protocols and specifications provided by the principal, earns a routine return for its research functions. Typical operating margins for contract research services in Europe range from 8% to 15%, depending on the specialisation, regulatory environment, and whether the CRO bears any development risk. Pharmaceutical distribution follows the same principles as general distribution — the limited-risk distributor earning a routine margin benchmarked via TNMM.

The most challenging area is pharmaceutical IP licensing and cost sharing arrangements. Where a group entity licenses drug patents to related parties, the royalty rate must be arm's length. CUP may apply where comparable license agreements for similar pharmaceutical compounds exist — databases such as RoyaltyStat and ktMINE provide comparable royalty data. However, for novel compounds with no direct comparables, more complex approaches (including profit split methods, residual profit allocation, or income-based valuation) are typically required. This tool implements CUP, Cost Plus, and TNMM — for profit split analysis of pharmaceutical IP, consult a transfer pricing specialist.

Recommended method: TNMM (Transactional Net Margin Method)

For healthcare entities, the tnmm (transactional net margin method) is typically the most appropriate transfer pricing method. This tool pre-selects this method based on industry best practice and OECD guidance. Typical arm's length ranges for healthcare are 8–15%.

Typical Healthcare intercompany transactions

Contract research services: A CRO subsidiary performs clinical trials, drug development, or laboratory services under contract to the IP-owning principal. Cost Plus is typical for routine CRO services. Preferred method: Cost Plus Method.

Distribution of pharmaceuticals: Related-party distributor purchases drugs from manufacturing affiliate and distributes to hospitals, pharmacies, and wholesalers. TNMM with operating margin for the distribution entity. Preferred method: TNMM (Transactional Net Margin Method).

IP licensing — drug patents and technology: Royalties charged for use of patented pharmaceutical compounds, formulations, or proprietary technology. CUP if comparable license agreements exist; otherwise, this may require profit split analysis (not implemented in this tool). Preferred method: CUP (Comparable Uncontrolled Price).

Regulatory context

Pharmaceutical TP is under intense global scrutiny. EU State Aid investigations have targeted pharmaceutical IP structures. Pillar Two GloBE rules (15% minimum tax) reduce incentives for aggressive pharmaceutical IP migration. BEPS Action 8-10 DEMPE framework fundamentally changed how pharma IP returns are allocated.

Limitation: Profit split analysis for pharmaceutical IP is NOT available in this tool. For cost sharing arrangements (OECD Chapter VIII), residual profit allocation, or intangible valuation, consult a transfer pricing specialist.